Josamycin

Name: Josamycin
Price: 226.00 USD

Catalog Number:

M001341915TOK

Mfr. No.:

TOK-J001

Price:

$226

Size:

Quantity:

Add to Cart:

Add to Cart

- Overview
  - Josamycin is a macrolide antibiotic that inhibits protein synthesis. It has anti-cancer properties, as it is able to overcome P-glycoprotein-dependent drug resistance in cancerous tumors.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Josamycin inhibits peptide elongation on the ribosome by binding close to the peptidyltransferase center and blocking the peptide exit tunnel in the large ribosomal subunit. Synthesis of full-length proteins is completely shut down by Josamycin.
- Properties
  - CAS Number
    
    16846-24-5
    
    Molecular Formula
    
    C42H69NO15
    
    Molecular Weight
    
    827.99
    
    Appearance
    
    White to light yellow powder
    
    Solubility
    
    Slightly soluble in ethanol, methanol and chloroform.
    
    Other Properties
    
    Source: Streptomyces kitasatoensis and Streptomyces narbonensis var. josamyceticus.
    Purity Level: ≥95%
    
    Storage
    
    2-8°C (protect from light and moisture)
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Gram-positive bacteria
    
    Eukaryotic Cell Culture Applications: Josamycin was evaluated in cell culture with peritoneal cells and splenic cells from BALB/c mice. Phagocytic activity of C. albicans and cytokine production (IL12 and IL-18) by peritoneal cells and IL-4 production by splenic cells was evaluated, and results indicated that Josamycin acts as an immunosuppressive agent (Ortega et al, 2004).
    
    Cancer Applications: Josamycin was found to increase the accumulation of vinblastine and cyclosporine A in a dose-dependent manner in anticancer drug-resistant cells (P388/ADR). Since it inhibits the binding of vinblastine and cyclosporine A to P-glycoprotein, it may be used to overcome anticancer drug resistance. In fact, combination chemotherapy with macrolide antibiotics like Josamycin may overcome P-glycoprotein-dependent drug-resistant tumors (Wang et al, 2000).